BIOMAT Database Logo BIOMAT Database Logo

Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. 1991

T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Second Department of Internal Medicine, Kobe University School of Medicine, Japan.

The immune mechanisms directly responsible for beta-cell destruction in insulin-dependent diabetes are undefined. We studied the role of MHC class I-restricted T lymphocytes in the development of diabetes in cyclophosphamide (CY)-treated male and untreated female NOD mice (H-2Kd,Db). After administration of CY to 10-wk-old male NOD/Shi/Kbe mice, 37 of 64 (58%) phosphate-buffered saline-injected control mice and 13 of 22 (59%) anti-Kb and 12 of 27 (44%) anti-Db monoclonal antibody (MoAb)-injected mice became diabetic by 14 wk of age, whereas only 3 of 38 (8%) anti-Kd and 2 of 13 (15%) anti-Lyt-2 MoAb-injected mice did. In untreated female NOD/Shi/Kbe mice, 30 of 46 (65%) mice developed spontaneous diabetes by 30 wk of age, whereas none of 9 anti-Kd MoAb-injected mice became diabetic. Immunohistochemical studies showed that islet-infiltrating cells in CY-treated control mice were composed mainly of both L3T4+ and Lyt-2+ T lymphocytes, whereas many L3T4+ and very few Lyt-2+ lymphocytes infiltrated within the islets in anti-Kd MoAb-injected mice. Administration of anti-Lyt-2 MoAb induced the absence of Lyt-2+ T lymphocytes in the islet and spleen. However, anti-Kd MoAb did not change the number of spleen cells or the T-lymphocyte subset and response to concanavalin A. These results suggest that MHC class I Kd-restricted Lyt-2+ T lymphocytes play an important role as direct effector cells in destruction of beta-cells in NOD/Shi/Kbe mice.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008817 Mice, Mutant Strains Mice bearing mutant genes which are phenotypically expressed in the animals. Mouse, Mutant Strain,Mutant Mouse Strain,Mutant Strain of Mouse,Mutant Strains of Mice,Mice Mutant Strain,Mice Mutant Strains,Mouse Mutant Strain,Mouse Mutant Strains,Mouse Strain, Mutant,Mouse Strains, Mutant,Mutant Mouse Strains,Mutant Strain Mouse,Mutant Strains Mice,Strain Mouse, Mutant,Strain, Mutant Mouse,Strains Mice, Mutant,Strains, Mutant Mouse
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Prevention of cyclophosphamide-induced diabetes by anti-V beta 8 T-lymphocyte-receptor monoclonal antibody therapy in NOD/Wehi mice.
November 1989, Diabetes,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice.
May 1991, Diabetes research (Edinburgh, Scotland),
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD mice by syngeneic splenocytes treated with cytotoxic drugs.
January 1991, Autoimmunity,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent.
April 1997, Journal of immunology (Baltimore, Md. : 1950),
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice.
March 1988, European journal of immunology,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Abrogation of islet immunogenicity using an anti-MHC class I monoclonal antibody.
June 1992, Transplantation proceedings,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Impaired mitogen-induced expression of high-affinity interleukin 2 receptors on spleen cells from NOD/Shi/Kbe mice.
September 1990, Diabetes,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
[Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody].
January 1992, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus.
April 1989, Diabetes,
T Taki, and M Nagata, and W Ogawa, and N Hatamori, and M Hayakawa, and J Hari, and K Shii, and S Baba, and K Yokono
Resistance to cyclophosphamide-induced diabetes in transgenic NOD mice expressing I-Ak.
January 1994, Autoimmunity,
Copied contents to your clipboard!